Sensars
Restore sensation before neuropathy becomes amputation.
Sensars is a closed-loop neurotechnology platform targeting the critical window before diabetic neuropathy progresses to ulcers, falls, and limb loss — restoring the sensory feedback loop that protects patients.
The Problem
The Missing Feedback Loop
Diabetic neuropathy silently destroys the sensory signals that keep patients safe. Sensars closes the loop.
Capital Partnership
Investment Thesis
Three reasons Sensars represents a category-defining opportunity.
Category-Defining Sensory Restoration
No approved closed-loop peripheral nerve stimulation device for diabetic neuropathy. Sensars is building the category from the ground up with strong IP positioning.
Clear Clinical Milestone
FDA Breakthrough Device designation accelerates the path to approval. The clinical evidence base is established — Sensars is executing the regulatory and commercial strategy.
Platform Upside Beyond Initial Indication
The closed-loop neurostimulation platform addresses neuropathy first but has clear expansion vectors into chronic pain, post-surgical recovery, and other sensory-deficit conditions.
Now Raising
Milestone capital for sensory restoration.
We're working with capital partners who understand the scale of this problem and the precision of this solution.
Connect with Adam ↗